designer491/iStock by way of Getty Images
The rivalry between Acelyrin (NASDAQ:SLRN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) is heating up, with both anticipated to launch probably market-moving information within the subsequent few months for his or her respective medication to deal with psoriatic arthritis, a market alternative that may very well be value greater than $10B.
Acelyrin and MoonLake have both developed IL-17 inhibitor therapies to deal with the pores and skin dysfunction hidradenitis suppurativa, or HS, and psoriatic arthritis, or PsA, a kind of arthritis that impacts folks with psoriasis. In the wake of a failed Acelyrin examine, MoonLake now seems to have the higher hand in HS, however the jury continues to be out for PsA.
Both shares had been feeding off one another over the previous few months. Shares of MoonLake soared 78% on June 26 after it reported constructive Phase 2 information for its drug sonelokimab, or SLK, within the therapy of HS. Investors rewarded Acelyrin as properly, pushing shares 35% greater. Acelyin made its market debut in May.
Acelryin was brutally punished on Sept. 11, nonetheless, when it reported {that a} Phase 2b/3 examine for its drug izokibep within the therapy of HS failed to satisfy its major endpoint at week 16. The inventory started tumbling in after-hours buying and selling and completed the Sept. 12 session 54% decrease. MoonLake shares, in the meantime, rose 10%.
“Izokibep is now in the rearview in HS, clearing the way for SLK to likely emerge as the preferred biologic in HS,” wrote BTIG analyst Julian Harrison in a current word, who has a purchase score on MoonLake.
The medication will face off once more within the subsequent a number of weeks, this time within the therapy of PsA, with MoonLake anticipated to report topline Phase 2 information on SLK within the first half of November and Acelyrin slated to report topline Phase 2b/3 information for izokibep in Q1 2024. MoonLake can be anticipated to launch further Phase 2 outcomes for SLK in HS in mid-October, based on analysts.
There’s additionally a 3rd horse within the race: UCB’s bimekizumab, or BZK. Like SLK and izokibep, BZK can be an IL-17 inhibitor. The drug is already marketed within the EU below the model title Bimzelx for plaque psoriasis, PsA and axial spondylarthritis.
UCB filed for EU approval of BZK for HS in July. The firm has additionally filed to have the drug permitted within the US for plaque psoriasis, with a call anticipated in Q3, based on a UCB assertion in late June.
According to Needham, SLK is predicted ship “at or above the best-in-class results achieved by bimekizumab” when MoonLake releases Phase 2 information in early November.
As for Acelryin, the failure of its Phase 2b/3 examine for HS “should not have any read-throughs to the PsA trial, but rates of discontinuations and adverse events related to injection site reactions at higher izokibep doses will be of interest,” based on Needham analyst Serge Belanger.
In a word launched Sept. 13, Morgan Stanley stated that whereas it nonetheless views Acelyrin as a “high potential” irritation and immunology platform, it believes upcoming information from MoonLake in October and November “may present an overhang on SLRN shares.” The financial institution lowered its score to equal weight, citing uncertainty on izokibep in HS.
“We therefore see a cleaner set-up for SLRN once this data flow is passed and the hurdle for izokibep in PsA is better established,” stated Morgan Stanley analyst Vikram Purohit in his word. “Generally, we see a clean and successful PsA readout in Q1 2024 as the next key milestone for re-instilling investor confidence.”
Needham projected the present market alternative for HS, psoriasis, PsA and a associated situation referred to as axial spondylarthritis at round $30B, reaching as excessive as $50B by the mid-2030s. It famous that MoonLake has estimated the present psoriatic arthritis market at round $6B, with potential to develop to $10B+ post-2030.
According to a Needham word dated Aug. 31, SLK demonstrated “best-in-class” potential and superior efficacy towards two main biologics to deal with the circumstances, particularly Novartis’s (NVS) Cosentyx for psoriasis and Abbvie’s (ABBV) Humira for HS. Needham at the moment has a purchase score on MoonLake.
BTIG can be bullish on MoonLake for psoriatic arthritis.
“We see a good chance of SLK emerging as a preferred treatment option in PsA and there is likely minimal credit in MLTX shares now for this additional blockbuster market opportunity beyond HS,” stated BTIG analyst Julian Harrison in a word dated Sept. 12.
Not surprisingly, hypothesis has been rising over whether or not MoonLake will probably be purchased and by whom, particularly after Reuters reported in mid-July that the biotech had been working with a financial institution on a attainable sale.
“We believe SLK ticks off all the major boxes as an attractive M&A candidate,” stated Needham’s Belanger in a word dated Aug. 31, including that they see massive pharma firms who have already got biologics within the house, such as Abbvie (ABBV), Johnson & Johnson (JNJ), Eli Lilly (LLY) and Novartis (NVS), as “the most likely buyers of MLTX.”
More on MoonLake and Acelyrin:
Acelyrin tanks, rival MoonLake rallies on failed scientific trial
Acelyrin, Inc. (SLRN) Q2 2023 Earnings Call Transcript
MoonLake Immunotherapeutics GAAP EPS of -$0.23 beats by $0.02
MoonLake jumps on report it is exploring a sale
Acelyrin closes 35% greater following drug replace by rival Moonlake
MoonLake Immunotherapeutics costs upsized $400M fairness providing at $50.00
MoonLake jumps 128% on Phase 2 win for pores and skin dysfunction candidate
Acelyrin up 28% following upsized IPO
